Sanofi Agreed to Produce Pfizer-BioNTech Vaccine

Sanofi has agreed to produce the Pfizer-BioNTech vaccine. The French company will supply vaccines to EU countries.

France-based pharmaceutical manufacturer Sanofi announced that they will produce the BioNTech-Pfizer vaccine to supply vaccines to European Union (EU) countries. In addition, the companies reached an agreement to further accelerate the coronavirus vaccination efforts. The French pharmaceutical company Sanofi announced that it will supply more than 125 million doses of mRNA vaccine for the European Union in the summer, in accordance with the agreement. Thanks to the agreement Sanofi has made with Biontech and Pfizer, it is aimed to accelerate the production of vaccines in the region to be distributed and to prevent economic losses. Experimental studies were suspended because the vaccine developed by Sanofi with GlaxoSmithKline Plc did not yield as strong a result as desired in elderly people in December. The fact that the vaccine studies failed to achieve the desired results in the clinical tests showed that the vaccine in question would not be ready until summer. According to the information provided by the French pharmaceutical company Sanofi, another interim clinical trial will begin in February. It was stated that this vaccine has the potential to hit the market in the fourth quarter.     You may also want to read this: Supply of Pfizer-BioNTech Vaccine to Europe Will Be Reduced This article has contributions of Bloomberg HT.